"Your presented facts have imo supported my opinion. Quite low dilution over a 4 year period as a general comparison to similar spec stocks over the same period."
Well, we are all entitled to our own opinion, as am I. If you think it supports your opinion, I'm ok with that. Yes, it may not be a bad result compared to many others out there, but it's far from the best too. I just think with a major on board for close to 4 years in a fast moving sector less regulated than full blown bio and with all the promises etc - it's a disappointing outcome, all things considered. Could be 2.5b in the blink of an eye with the change of business direction - wait and see.
OBJ Price at posting:
3.4¢ Sentiment: None Disclosure: Held
(20min delay)